CaraMed Capital is hoping to raise up to $50 million for its first fund. CaraMed Capital, formed by four experienced healthtech executives, entrepreneurs and investors, is hoping to raise up to $50 million for the country’s first specialised deep healthtech venture capital fund. Managing partner Caroline Quay had a vision for building globally successful healthtech companies in New Zealand after working for healthtech success story NZX-listed Fisher & Paykel Healthcare and then helping with the ASX listing of Auckland-based tissue repair and regeneration company Aroa Biosurgery at a A$225m market capitalisation. Quay, a former lawyer, is chief investment officer for Cure Kids Ventures, which is a seed and early-stage investment fund that invests in the